Guggenheim initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Reports Q3 2025 Financial Results
- Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
- Foghorn Therapeutics CFO Kristian Humer Resigns
- Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
- Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating